Sfoglia per Autore
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
2007 Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M.
New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib
2008 Martinelli, G.; Iacobucci, I.; Cilloni, D.; Giannoulia, P.; Soverini, S.; Piccaluga, P.P.; Papayannidis, C.; Paolini, S.; Terragna, C.; Amabile, M.; Colarossi, S.; Gnani, A.; Pane, F.; Saglio, G.; Baccarani, M.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
2008 Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Tozzuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
2008 Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML.
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION
2009 Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G.
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience
2009 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia
2009 Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
2009 Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party.
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
2009 Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; Rosti G; Baccarani M.
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
2009 Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G.
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP.
2009 Testoni N; Marzocchi G; Luatti S; Amabile M; Baldazzi C; Stacchini M; Nanni M; Rege-Cambrin G; Giugliano E; Giussani U; Abruzzese E; Kerim S; Grimoldi MG; Gozzetti A; Crescenzi B; Carcassi C; Bernasconi P; Cuneo A; Albano F; Fugazza G; Zaccaria A; Martinelli G; Pane F; Rosti G; Baccarani M.
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP
2009 Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G.
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
2009 Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R.
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience
2010 Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis
2010 Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
2010 Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients.
2011 Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobucci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
2011 Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pregno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G.
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
2011 Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Specchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. | Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin ...R; Martinelli G; Baccarani M. | 2007-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib | Martinelli, G.; Iacobucci, I.; Cilloni, D.; Giannoulia, P.; Soverini, S.; Piccaluga, P.P.; Papaya...nnidis, C.; Paolini, S.; Terragna, C.; Amabile, M.; Colarossi, S.; Gnani, A.; Pane, F.; Saglio, G.; Baccarani, M. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 4.01 Contributo in Atti di convegno | - |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T,... Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. | Bocchia M; Ippoliti M; Gozzetti A; Abruzzese E; Calabrese S; Amabile M; Pirrotta MT; Crupi R; Toz...zuoli D; Trawinska MM; Defina M; Martinelli G; Lauria F. | 2008-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. | Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F;... De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION | Colarossi, S.; Gnani, A.; Soverini, S.; Castagnetti, F.; Marzocchi, G.; Luatti, S.; Astolfi, A.; ...Formica, S.; Iacobucci, I.; Lonetti, A.; Palandri, F.; Poerio, A.; Amabile, M.; Rosti, G.; Pession, A.; Testoni, N.; Baccarani, M.; Martinelli, G. | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Baldazzi, Carmen; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Castagnetti, Fausto; Poerio, Angela; Clissa, Cristina; Parisi, Sarah; Polverelli, Nicola; Guadagnuolo, Viviana; Pier Paolo Piccaluga, ; Rosti, Gianantonio; Baccarani, Michele; Martinelli, Giovanni | 2009-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |
| Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia | Soverini, Simona; Gnani, Alessandra; Colarossi, Sabrina; Vitale, Antonella; Castagnetti, Fausto; ...Palandri, Francesca; Paolini, Stefania; Papayannidis, Cristina; Amabile, Marilina; Iacobucci, Ilaria; Poerio, Angela; Scotlandi, Katia; Lonetti, Annalisa; Mandelli, Franco; Baccarani, Michele; Foà, Robin; Martinelli, Giovanni | 2009-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. | Rosti G; Palandri F; Castagnetti F; Breccia M; Levato L; Gugliotta G; Capucci A; Cedrone M; Fava ...C; Intermesoli T; Cambrin GR; Stagno F; Tiribelli M; Amabile M; Luatti S; Poerio A; Soverini S; Testoni N; Martinelli G; Alimena G; Pane F; Saglio G; Baccarani M; GIMEMA CML Working Party. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure | Palandri F; Castagnetti F; Soverini S; Poerio A; Gugliotta G; Luatti S; Amabile M; Martinelli G; ...Rosti G; Baccarani M. | 2009-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de... Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. | Testoni N; Marzocchi G; Luatti S; Amabile M; Baldazzi C; Stacchini M; Nanni M; Rege-Cambrin G; Gi...ugliano E; Giussani U; Abruzzese E; Kerim S; Grimoldi MG; Gozzetti A; Crescenzi B; Carcassi C; Bernasconi P; Cuneo A; Albano F; Fugazza G; Zaccaria A; Martinelli G; Pane F; Rosti G; Baccarani M. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP | Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Re...ge Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. | Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R;... Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R. | 2009-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience | Papayannidis, Cristina; Iacobucci, Ilaria; Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandr...a; Lonetti, Annalisa; Ferrari, Anna; Testoni, Nicoletta; Amabile, Marilina; Ottaviani, Emanuela; Maria Chiara Abbenante, ; Curti, Antonio; Paolini, Stefania; Lama, Barbara; Clissa, Cristina; Parisi, Sarah; Guadagnuolo, Viviana; Baccarani, Michele; Martinelli, Giovanni | 2010-01-01 | CANCER RESEARCH | - | 4.02 Riassunto (Abstract) | - |
| Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis |
Castagnetti F; Testoni N;Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo... A;Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G |
2010-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N...; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M | 2010-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Overexpression of FBP1 is Associated to High Sokal Risk in Chronic Myeloid Leukemia Patients. | Durante, S; Terragna, C; Astolfi, A; Palandri, F; Castagnetti, F; Testoni, N; Amabile, M; Iacobuc...ci, I; Soverini, S; Alimena, G; Breccia, M; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Martinelli, G | 2011-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. | Gugliotta G.; Castagnetti F.; Palandri F.; Breccia M.; Intermesoli T.; Capucci A.; Martino B.; Pr...egno P.; Rupoli S.; Ferrero D.; Gherlinzoni F.; Montefusco E.; Bocchia M.; Tiribelli M.; Pierri I.; Grifoni F.; Marzocchi G.; Amabile M.; Testoni N.; Martinelli G.; Alimena G.; Pane F.; Saglio G.; Baccarani M.; Rosti G. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. | Marzocchi G.; Castagnetti F.; Luatti S.; Baldazzi C.; Stacchini M.; Gugliotta G.; Amabile M.; Spe...cchia G.; Sessarego M.; Giussani U.; Valori L.; Discepoli G.; Montaldi A.; Santoro A.; Bonaldi L.; Giudici G.; Cianciulli A.M.; Giacobbi F.; Palandri F.; Pane F.; Saglio G.; Martinelli G.; Baccarani M.; Rosti G.; Testoni N. | 2011-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile